Literature DB >> 5312993

Serological studies on cholera patients and their household contacts in Calcutta in 1968. Joint ICMR-GWB-WHO Cholera Study Group, Calcutta, India.

.   

Abstract

Vibriocidal and agglutination tests have been performed, using a microtechnique, on 170 pairs of sera obtained, at intervals of 13-26 days, from bacteriologically proven cholera patients and their contacts, carriers and vibrio-negative contacts. Of the carriers, 44%-46% of those with low initial vibriocidin titres (</= 1:80) and 28%-37% of those having high initial titres (</= 1:160) showed a 4-fold or greater rise in vibriocidal titres. Carriers and negative contacts exhibited almost similar pictures. With an increase in the number of carriers per household, a larger number of negative contacts developed significant titres in their second samples. In general, initial titres increased with age, but were highest in the 10-25-years age-group: however, 30% of children below 10 years of age had titres >/= 1:640. The results indicated that individuals with high titres might become carriers but may not suffer from overt cholera.The investigation also showed that retrospective diagnosis of cholera infection in a highly endemic area should not depend on serology alone.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5312993      PMCID: PMC2427674     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  9 in total

1.  Cholera carrier studies in Calcutta in 1966-67.

Authors:  R Sinha; B C Deb; S P De; A H Abou-Gareeb; D L Shrivastava
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

2.  Role of carriers in the epidemiology of cholera in Calcutta.

Authors:  R Sinha; B C Deb; S P De; B K Sirkar; A H Abou-Gareeb; D L Shrivastava
Journal:  Indian J Med Res       Date:  1968-07       Impact factor: 2.375

3.  Vibriocidal antibody titrations: a comparison of three methods.

Authors:  B C Deb; R Sinha; D L Shrivastava
Journal:  Indian J Med Res       Date:  1969-01       Impact factor: 2.375

4.  Vibriocidal test and its parameters.

Authors:  R Ganguly; B C Deb; D L Shrivastava
Journal:  Indian J Med Res       Date:  1969-05       Impact factor: 2.375

5.  Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae.

Authors:  W H Mosley; W M McCormack; A Ahmed; A K Chowdhury; R K Barui
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

6.  Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.

Authors:  A S Benenson; A Saad; W H Mosley
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

7.  Serological studies in cholera. I. Vibrio agglutinin response of cholera patients determined by a microtechnique.

Authors:  A S Benenson; A Saad; M Paul
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

8.  The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients.

Authors:  W H Mosley; S Ahmad; A S Benenson; A Ahmed
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

9.  Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 3. The lack of effect of prior vaccination or circulating vibriocidal antibody on the severity of clinical cholera.

Authors:  W M McCormack; A S Rahman; A K Chowdhury; W H Mosley; R A Phillips
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

  9 in total
  1 in total

Review 1.  Chemoprophylaxis in contacts of patients with cholera: systematic review and meta-analysis.

Authors:  Ludovic Reveiz; Evelina Chapman; Pilar Ramon-Pardo; Tracey Perez Koehlmoos; Luis Gabriel Cuervo; Sylvain Aldighieri; Amy Chambliss
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.